These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 36912128

  • 1. Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma.
    Wang X, Yu L, Jiang X, Ding K.
    Cancer Med; 2023 May; 12(9):10553-10562. PubMed ID: 36912128
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88mut /CD79Bmut diffuse large B-cell lymphoma.
    Deng T, Zhang S, Xiao M, Gu J, Huang L, Zhou X.
    Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
    [Abstract] [Full Text] [Related]

  • 6. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
    Ladetto M, Cortelazzo S, Ferrero S, Evangelista A, Mian M, Tavarozzi R, Zanni M, Cavallo F, Di Rocco A, Stefoni V, Pagani C, Re A, Chiappella A, Balzarotti M, Zilioli VR, Gomes da Silva M, Arcaini L, Molinari AL, Ballerini F, Ferreri AJM, Puccini B, Benedetti F, Stefani PM, Narni F, Casaroli I, Stelitano C, Ciccone G, Vitolo U, Martelli M.
    Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
    Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C.
    Ann Oncol; 2019 Apr 01; 30(4):621-628. PubMed ID: 30698644
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
    Kimani S, Painschab MS, Kaimila B, Kasonkanji E, Zuze T, Tomoka T, Mulenga M, Nyasosela R, Chikasema M, Mtangwanika A, Chawinga M, Mhango W, Nicholas S, Chimzimu F, Kampani C, Krysiak R, Lilly A, Randall C, Seguin R, Westmoreland KD, Montgomery ND, Fedoriw Y, Gopal S.
    Lancet Glob Health; 2021 Jul 01; 9(7):e1008-e1016. PubMed ID: 34022150
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study.
    He HX, Gao Y, Bai B, Wang XX, Li JB, Huang C, Mao JY, Ping LQ, Rong QX, He YX, Huang H, Cai QQ, Li ZM, Jiang WQ, Huang HQ.
    Cancer Med; 2021 Nov 01; 10(21):7650-7664. PubMed ID: 34581023
    [Abstract] [Full Text] [Related]

  • 15. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ, Hu LY, Geng QR, Chen J, Lu ZH, Rao HL, Liu Q, Jiang WQ, Huang HQ, Lin TY, Xia ZJ.
    Chin J Cancer; 2016 Sep 13; 35(1):87. PubMed ID: 27624700
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.
    Nowakowski GS, Willenbacher W, Greil R, Larsen TS, Patel K, Jäger U, Manges RF, Trümper L, Everaus H, Kalakonda N, Brown P, Jørgensen JM, Cunningham D, Dell'Aringa J, Fox B, Rubio ND, Kilavuz N, Casadebaig ML, Manzke O, Munoz J.
    Int J Hematol; 2022 Feb 13; 115(2):222-232. PubMed ID: 34797531
    [Abstract] [Full Text] [Related]

  • 18. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB, LaPlant B, McPhail E, Habermann TM, Inwards DJ, Micallef IN, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE.
    Lancet Haematol; 2016 Jul 13; 3(7):e309-16. PubMed ID: 27374464
    [Abstract] [Full Text] [Related]

  • 19. The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis.
    Rozental A, Gafter-Gvili A, Vidal L, Raanani P, Gurion R.
    Hematol Oncol; 2019 Feb 13; 37(1):27-34. PubMed ID: 30216478
    [Abstract] [Full Text] [Related]

  • 20. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
    Sehn LH, Martelli M, Trněný M, Liu W, Bolen CR, Knapp A, Sahin D, Sellam G, Vitolo U.
    J Hematol Oncol; 2020 Jun 06; 13(1):71. PubMed ID: 32505213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.